2426-19-9

Basic information

• Product Name: 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE
• Synonyms: 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE;(5-methoxy-1H-indol-3-yl)oxoacetyl chloride;2-(5-Methoxy-1H-indol-3-yl)-2-oxoacetyl chloride;1H-INDOLE-3-ACETYL CHLORIDE, 5-METHOXY-α-OXO-
• CAS NO: 2426-19-9
• Molecular Formula: C₁₁H₈ClNO₃
• Molecular Weight: 237.64
• Mol File: 2426-19-9.mol
• Article Data: 48

Chemical Properties

• Boiling Point: 445.791°C at 760 mmHg
• Flash Point: 223.407°C
• Appearance: /
• Density: 1.432g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.645
• Storage Temp.: Room Temperature
• Solubility: DMSO
• CAS DataBase Reference: 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE(2426-19-9)
• EPA Substance Registry System: 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE(2426-19-9)

Safety Data

• Hazardous Substances Data: 2426-19-9(Hazardous Substances Data)

Usage

Uses

5-Methoxy-α-oxo-1H-indole-3-acetyl Chloride is an intermediate used in the synthesis of 5-Methoxy-N-methyl-N-isopropyl Tryptamine (M271680), which is a psychedelic tryptamine related to N-methyl-N-isopropyltryptamine. 5-Methoxy MiPT potently inhibits the re-uptake of the monoamines serotonin and norepinephrine but does not affect dopamine re-uptake. 5-Methoxy MiPT has no effect on the release of monoamines from rat brain synaptosomes. This product is intended for forensic and research applications.

InChI:InChI=1/C11H8ClNO3/c1-16-6-2-3-9-7(4-6)8(5-13-9)10(14)11(12)15/h2-5,13H,1H3

Upstream product

• 1006-94-6 5-methoxylindole 
• 79-37-8 oxalyl dichloride 
• 60-29-7 diethyl ether 

Downstream Products

• 99988-56-4 methyl 2-(5-methoxy-1H-indol-3-yl)-2-oxoacetate 
• 608-07-1 2-(5-methoxyindol-3-yl)ethylamine 
• 3949-14-2 1-(5-Methoxy-indol-3-yl)-2-pyrrolidino-ethan 
• 1019-45-0 N,N-dimethyl-5-methoxytryptamine 
• 23304-48-5 (5-methoxy-1H-indol-3-yl)acetic acid methyl ester 
• 3471-31-6 5-methoxy-1H-indole-3-acetic acid 
• 1067133-53-2 C₂₄H₂₈O₄N₂ 
• 52055-22-8 2-(5-methoxy-1H-indol-3-yl)-2-oxo-acetamide 
• 134937-85-2 N-(2,6-Dichloro-phenyl)-2-(5-methoxy-1H-indol-3-yl)-2-oxo-acetamide 
• 122334-70-7 (R)-2-[2-(5-Methoxy-1H-indol-3-yl)-2-oxo-acetylamino]-3-phenyl-propionic acid ethyl ester 
• 94732-36-2 (S)-2-[2-(5-Methoxy-1H-indol-3-yl)-2-oxo-acetylamino]-3-phenyl-propionic acid ethyl ester 
• 119284-52-5 N-[2-(3,4-Dihydroxy-phenyl)-ethyl]-2-(5-methoxy-1H-indol-3-yl)-2-oxo-acetamide 
• 97529-62-9 2-[2-(5-Methoxy-1H-indol-3-yl)-2-oxo-acetylamino]-3-phenyl-propionic acid ethyl ester 

Relevant articles and documents

A one-pot tandem Pictet-Spengler-Diels-Alder synthesis of apoyohimbines from 3-carbomethoxy-2-(formylmethyl)-3-sulfolene

Pictet-Spengler reactions were carried out between 3-carbomethoxy-2-(formylmethyl)-3-sulfolene and tryptamines. Without isolation, die products were converted with complete stereoselectivity into apoyohimbine derivatives, via sulfur dioxide extrusion followed by intramolecular Diels-Alder cyclisation.

PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N, N-DIMETHYLTRYPTAMINE

An intranasal composition comprises a dosage amount of 50 to 150 mg / ml of 5-methoxy-N, N-dimethyltryptamine (5 MeODMT) in a liquid medium, 5MeODMT being formulated as a chloride salt of 5MeODMT (chlrorhydrate of 5MeODMT) and hydrochloride of 5MeODMT bei

2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS

2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).